211 related articles for article (PubMed ID: 27153560)
1. Circulating tumor cells as a prognostic and predictive marker in gastrointestinal stromal tumors: a prospective study.
Li Q; Zhi X; Zhou J; Tao R; Zhang J; Chen P; Røe OD; Sun L; Ma L
Oncotarget; 2016 Jun; 7(24):36645-36654. PubMed ID: 27153560
[TBL] [Abstract][Full Text] [Related]
2. [Significance of circulating tumor cell monitoring in targeted therapy for gastrointestinal stromal tumors].
Fan JB; Zhi XF; Chen SS; Zhu JW
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Sep; 24(9):789-795. PubMed ID: 34530560
[No Abstract] [Full Text] [Related]
3. Detection of ANO1 mRNA in PBMCs is a promising method for GISTs diagnosis.
Li H; Wu A; Zhu W; Hou F; Cheng S; Cao J; Yan Y; Zhang C; Liu Z
Sci Rep; 2019 Jul; 9(1):9525. PubMed ID: 31266974
[TBL] [Abstract][Full Text] [Related]
4. DOG1 regulates growth and IGFBP5 in gastrointestinal stromal tumors.
Simon S; Grabellus F; Ferrera L; Galietta L; Schwindenhammer B; Mühlenberg T; Taeger G; Eilers G; Treckmann J; Breitenbuecher F; Schuler M; Taguchi T; Fletcher JA; Bauer S
Cancer Res; 2013 Jun; 73(12):3661-70. PubMed ID: 23576565
[TBL] [Abstract][Full Text] [Related]
5. Expression of cell cycle regulators and frequency of TP53 mutations in high risk gastrointestinal stromal tumors prior to adjuvant imatinib treatment.
Ihle MA; Huss S; Jeske W; Hartmann W; Merkelbach-Bruse S; Schildhaus HU; Büttner R; Sihto H; Sundby Hall K; Eriksson M; Reichardt P; Joensuu H; Wardelmann E
PLoS One; 2018; 13(2):e0193048. PubMed ID: 29451912
[TBL] [Abstract][Full Text] [Related]
6. [Gastrointestinal stromal tumor and renal transplant].
Seculini Patiño CE; Tabares AH; Laborie MV; Diller A
Medicina (B Aires); 2017; 77(4):334-336. PubMed ID: 28825581
[TBL] [Abstract][Full Text] [Related]
7. Analysis of clinicopathological and immunohistochemical parameters and correlation of outcomes in gastrointestinal stromal tumors.
Varshney VK; Gupta RK; Saluja SS; Tyagi I; Mishra PK; Batra VV
Indian J Cancer; 2019; 56(2):135-143. PubMed ID: 31062732
[TBL] [Abstract][Full Text] [Related]
8. Oncogene mutational analysis in imatinib naive population of gastrointestinal stromal tumor patients.
Ali Abuderman AW; M Aldakheel F
Cell Mol Biol (Noisy-le-grand); 2020 Dec; 66(8):26-32. PubMed ID: 34174973
[TBL] [Abstract][Full Text] [Related]
9. Gastrointestinal stromal tumors: diagnosis and treatment.
Acín-Gándara D; Pereira-Pérez F; Castaño-Pascual A; Durán-Poveda M; Antequera-Pérez A; Miliani-Molina C
Cir Cir; 2012; 80(1):44-51. PubMed ID: 22472152
[TBL] [Abstract][Full Text] [Related]
10. Is DOG1 Immunoreactivity Specific to Gastrointestinal Stromal Tumor?
Swalchick W; Shamekh R; Bui MM
Cancer Control; 2015 Oct; 22(4):498-504. PubMed ID: 26678977
[TBL] [Abstract][Full Text] [Related]
11. Serum miR-518e-5p is a potential biomarker for secondary imatinib-resistant gastrointestinal stromal tumor.
Kou Y; Yang R; Wang Q
J Biosci; 2018 Dec; 43(5):1015-1023. PubMed ID: 30541960
[TBL] [Abstract][Full Text] [Related]
12. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial.
Joensuu H; Eriksson M; Sundby Hall K; Hartmann JT; Pink D; Schütte J; Ramadori G; Hohenberger P; Duyster J; Al-Batran SE; Schlemmer M; Bauer S; Wardelmann E; Sarlomo-Rikala M; Nilsson B; Sihto H; Monge OR; Bono P; Kallio R; Vehtari A; Leinonen M; Alvegård T; Reichardt P
JAMA; 2012 Mar; 307(12):1265-72. PubMed ID: 22453568
[TBL] [Abstract][Full Text] [Related]
13. Characterizing gastrointestinal stromal tumors and evaluating neoadjuvant imatinib by sequencing of endoscopic ultrasound-biopsies.
Hedenström P; Nilsson B; Demir A; Andersson C; Enlund F; Nilsson O; Sadik R
World J Gastroenterol; 2017 Aug; 23(32):5925-5935. PubMed ID: 28932084
[TBL] [Abstract][Full Text] [Related]
14. Postoperative imatinib in patients with intermediate risk gastrointestinal stromal tumor.
Wu X; Li J; Xu W; Gao J; Li Y; Shen L
Future Oncol; 2018 Jul; 14(17):1721-1729. PubMed ID: 29969914
[TBL] [Abstract][Full Text] [Related]
15. Genetic polymorphisms in angiogenesis-related genes are associated with worse progression-free survival of patients with advanced gastrointestinal stromal tumours treated with imatinib.
Verboom MC; Kloth JSL; Swen JJ; van der Straaten T; Bovée JVMG; Sleijfer S; Reyners AKL; Mathijssen RHJ; Guchelaar HJ; Steeghs N; Gelderblom H
Eur J Cancer; 2017 Nov; 86():226-232. PubMed ID: 29054076
[TBL] [Abstract][Full Text] [Related]
16. GIST Manifesting as a Retroperitoneal Tumor: Clinicopathologic Immunohistochemical, and Molecular Genetic Study of 112 Cases.
Miettinen M; Felisiak-Golabek A; Wang Z; Inaguma S; Lasota J
Am J Surg Pathol; 2017 May; 41(5):577-585. PubMed ID: 28288036
[TBL] [Abstract][Full Text] [Related]
17. SLITRK3 expression correlation to gastrointestinal stromal tumor risk rating and prognosis.
Wang CJ; Zhang ZZ; Xu J; Wang M; Zhao WY; Tu L; Zhuang C; Liu Q; Shen YY; Cao H; Zhang ZG
World J Gastroenterol; 2015 Jul; 21(27):8398-407. PubMed ID: 26217092
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Tolerability of 5-Year Adjuvant Imatinib Treatment for Patients With Resected Intermediate- or High-Risk Primary Gastrointestinal Stromal Tumor: The PERSIST-5 Clinical Trial.
Raut CP; Espat NJ; Maki RG; Araujo DM; Trent J; Williams TF; Purkayastha DD; DeMatteo RP
JAMA Oncol; 2018 Dec; 4(12):e184060. PubMed ID: 30383140
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of Long-Term Adjuvant Therapy With Imatinib Mesylate After Extensive Surgical Treatment for Ruptured Gastrointestinal Stromal Tumors of the Small Intestine With Peritoneal Metastases: A Case Report.
Kimura T; Togawa T; Onishi K; Iida A; Sato Y; Goi T
J Investig Med High Impact Case Rep; 2020; 8():2324709620970736. PubMed ID: 33228387
[TBL] [Abstract][Full Text] [Related]
20. The Role of Surgery in Metastatic Gastrointestinal Stromal Tumors.
Keung EZ; Fairweather M; Raut CP
Curr Treat Options Oncol; 2016 Feb; 17(2):8. PubMed ID: 26820287
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
